FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
REDWOOD CITY, Calif., Nov. 10, 2016 -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that management will present at the 7th Annual Craig-Hallum Alpha Select Conference on Wednesday, November 16, at 11:20 a.m. Eastern time (8:20 a.m. Pacific time). The conference is being held at the Sheraton Times Square Hotel in New York City.
A live webcast and replay of the presentation will be available on the Investors section of the company's website, http://ir.codexis.com/.
About Codexis, Inc.
Codexis, Inc. is a leading developer of biocatalysts for pharmaceutical and fine chemical production. The company’s patent portfolio includes more than 850 patents and patent applications worldwide that cover its novel enzymes and proprietary methods for engineering new enzymes and their applications. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Contacts:
Investors
LHA
Jody Cain, 310 691 7100
[email protected]
Media
That’s Nice LLC
Guy Tiene
[email protected]
